<DOC>
	<DOCNO>NCT00016679</DOCNO>
	<brief_summary>This study determine optimal dose 1-octanol safely reduce tremor patient essential tremor-a disorder hand , sometimes head , shake involuntarily . Current treatment may ineffective produce unwanted side effect . Ethanol ( chemical beer wine cause intoxication ) reduce tremor many patient , patient generally n't use regularly interferes daily activity . Laboratory study show 1-octanol , drug similar ethanol , may beneficial effect tremor less likelihood intoxication . Patients 21 year age older essential tremor may eligible 10-day study . Candidates evaluate neurological examination , blood test , urinalysis electrocardiogram ( EKG ) . Those enrol admit hospital 4 day 1-octanol administration monitoring . On day 1 , patient medical history physical examination . A catheter ( thin plastic tube ) place vein forearm sampling blood . Patients take one 1-octanol capsule ( one seven dos ) mouth monitor tremor drug side effect . Blood sample periodically first 3 hour determine 1-octanol blood level . On day 2 3 , patient monitor additional side effect . On day 3 4 , laboratory test ( blood urine ) do evaluate liver kidney function . On day 4 , catheter remove patient discharge hospital . A follow-up visit schedule 1 week discharge physical examination blood , urine EKG test .</brief_summary>
	<brief_title>1-Octanol Treat Essential Tremor</brief_title>
	<detailed_description>Essential tremor common movement disorder affect approximately 1.4 % population . Response medication beta blocker mysoline may partial accompanied intolerable side effect . Roughly 80 % patient significant tremor reduction ethanol although daily use treatment potentially serious social legal consequence . The lead hypothesis pathophysiology essential tremor unmask spontaneous oscillation neuron inferior olive . Both ethanol 1-octanol show reduce spontaneous oscillation animal model essential tremor ; however , 1-octanol dose dose much low intoxicate dose suggesting may useful treatment essential tremor . Our initial study 1-octanol low , single dose patient essential tremor suggest efficacious safe . This present study plan identify maximum tolerate dose broaden safety efficacy data human . Additionally , hope collect information pharmacokinetics 1-octanol . This study design phase Ia , unblinded , inpatient study adult essential tremor receive escalate dos 1-octanol . Cohorts three begin dose escalation dose previously study . Each cohort follow inpatient set 72 hour ( outpatient 1 additional week ) adverse event , pharmacokinetics efficacy assess . If subject achieve dose-limiting toxicity , 3 additional subject recruit receive next high dose . If 1/3 subject achieve dose-limiting toxicity , next cohort receive dose . Dose limit toxicity define dose produce dose-limiting toxicity least 2 subject . Maximum tolerate dose define next low dose . With study , hope identify range dos may useful treatment essential tremor combine pharmacokinetic efficacy data , design protocol study multiple dose regimen long time period .</detailed_description>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients essential tremor history ethanol responsiveness . Patients must medication use treat essential tremor mysoline propranalol least 2 week . Patients must withhold ethanol caffeine 24 hour prior start study study termination ( 10 day ) . EXCLUSION CRITERIA : Patients abnormality neurologic exam tremor . Patients history chronic alcohol dependence . Patients chronic medical condition renal failure , hepatic failure chronic lung disease . Patients chronic medication temporarily discontinue length study ( 10 day ) . Patients , moral religious reason wish take potentially intoxicating drug . Patients abnormality baseline screen laboratory test . Women pregnant lactating . People Asian decent may differ pharmocogenetically respect alcohol aldehyde dehydrogenase may increase sensitivity alcohol metabolite</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Side Effects</keyword>
	<keyword>Essential Tremor</keyword>
	<keyword>Tremor</keyword>
	<keyword>Movement Disorder</keyword>
</DOC>